Successful Drug Discovery - Volume 5
Reduzierte Artikel in dieser Kategorie
2,99 €
| Verlag | Wiley-VCH |
| Auflage | 2021 |
| Seiten | 320 |
| Format | 17,6 x 1,8 x 25,2 cm |
| Gewicht | 762 g |
| Artikeltyp | Englisches Buch |
| ISBN-10 | 3527347542 |
| EAN | 9783527347544 |
| Bestell-Nr | 52734754A |
In the fifth volume of Successful Drug Discovery, the inventors and primary developers of drugs that made it to the market tell the story of the drug's discovery and development. Case studies of drugs from different therapeutic fields reveal the all-too-often unpredictable path from the first drug candidate molecule to the successfully marketed drug. In addition, this new volume addresses overarching topics for drug discovery, such as drug discovery in academia, and discusses currently important classes of small molecule as well as biological drugs. Comprehensive in scope, the book?s nine chapters provide a representative cross-section of the present-day drug development effort.
The authoritative fifth volume is filled with relevant data and chemical information, as well as the insight and experience of the best contemporary drug creators. This important volume:
- Puts the focus on recently introduced drugs that have not yet made it into standard textbooks or general re ferences
- Contains information and insight that is new and often not even available from the primary literature
- Reveals what it takes to successfully develop a drug molecule that has made it all the way to the market
- Is endorsed and supported by the International Union of Pure and Applied Chemistry (IUPAC)
Written for medicinal chemists, pharmaceutical chemists, organic chemists, Successful Drug Discovery, Volume Five reveals the most recent techniques used by drug innovators in the drug development process.
Inhaltsverzeichnis:
PART I: GENERAL ASPECTS
Drug Discovery in Academia
From Degraders to Molecular Glues - New Ways of Breaking Down Disease-Associated Proteins
PART II: DRUG CLASS STUDIES
GLP-1 Receptor Agonists for the Treatment of Type-2 Diabetes and Obesity
Recent advances on SGLT2 inhibitors: Synthetic approaches, therapeutic benefits and adverse events
CAR T cells - a Novel Biological Drug Class
CGRP-Inhibitors for the Treatment of Migraine
PART III: CASE STUDIES
Discovery and Development of Emicizumab (HEMLIBRA), a humanized bispecific antibody to coagulation factors IXa and X with a factor VIII cofactor activity
Discovery and Development of Ivosidenib (AG-120; TIBSOVO)
The discovery of Kisqali (ribociclib), a CDK4/6 inhibitor for the treatment of HR positive/HER2 negative advanced breast cancer
